Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients

Autor: Essack Mitha, Gergely Krivan, Frederique Jacobs, Arnon Nagler, Sally Alrabaa, Analia Mykietiuk, Andrew Kenwright, Sophie Le Pogam, Barry Clinch, Loreta Vareikiene

Publikováno v: Infectious Diseases and Therapy, Vol 8, Iss 4, Pp 613-626 (2019)

Abstract Introduction Immunocompromised patients infected with influenza exhibit prolonged viral shedding and higher risk of resistance. Optimized treatment strategies are needed to reduce the risk of antiviral resistance. This phase IIIb, randomized

Externí odkaz: https://doaj.org/article/e7323e96cc084a1398b12a73bf55c421

Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19

Autor: Jane, O'Halloran, Eyal, Kedar, Kevin J, Anstrom, Matthew W, McCarthy, Emily R, Ko, Patricia, Segura Nunez, Cynthia, Boucher, P Brian, Smith, Reynold A, Panettieri, Sabina, Mendivil Tuchia de Tai, Martin, Maillo, Akram, Khan, Alfredo J, Mena Lora, Matthias, Salathe, Gerardo, Capo, Daniel, Rodriguez Gonzalez, Thomas F, Patterson, Christopher, Palma, Horacio, Ariza, Maria, Patelli Lima, Anne M, Lachiewicz, John, Blamoun, Esteban, Nannini, Eduardo, Sprinz, Analia, Mykietiuk, Radica, Alicic, Adriana M, Rauseo, Cameron R, Wolfe, Britta, Wittig, Daniel K, Benjamin, Steven E, McNulty, Pearl, Zakroysky, Susan, Halabi, Sandra, Butler, Jane, Atkinson, Stacey J, Adam, Richard, Melsheimer, Soju, Chang, Lisa, LaVange, Michael, Proschan, Samuel A, Bozzette, William G, Powderly

Publikováno v: medRxiv

BackgroundImmune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care.MethodsWe conducted a mast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c636f160d614202fc158d1f4336836d
https://pubmed.ncbi.nlm.nih.gov/36172138

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

Autor: Richard T Davey, Eduardo Fernández-Cruz, Norman Markowitz, Sarah Pett, Abdel G Babiker, Deborah Wentworth, Surender Khurana, Nicole Engen, Fred Gordin, Mamta K Jain, Virginia Kan, Mark N Polizzotto, Paul Riska, Kiat Ruxrungtham, Zelalem Temesgen, Jens Lundgren, John H Beigel, H Clifford Lane, James D Neaton, Jessica Butts, Eileen Denning, Alain DuChene, Eric Krum, Merrie Harrison, Sue Meger, Ross Peterson, Kien Quan, Megan Shaughnessy, Greg Thompson, David Vock, Julia Metcalf, Robin Dewar, Tauseef Rehman, Ven Natarajan, Rose McConnell, Emily Flowers, Kenny Smith, Marie Hoover, Elizabeth M Coyle, David Munroe, Bitten Aagaard, Mary Pearson, Adam Cursley, Helen Webb, Fleur Hudson, Charlotte Russell, Aminata Sy, Cara Purvis, Brooke Jackson, Yolanda Collaco-Moraes, Dianne Carey, Rosemary Robson, Adriana Sánchez, Elizabeth Finley, Donna Conwell, Marcelo H Losso, Luciana Gambardella, Cecilia Abela, Paco Lopez, Helena Alonso, Giota Touloumi, Vicky Gioukari, Olga Anagnostou, Anchalee Avihingsanon, Kanitta Pussadee, Sasiwimol Ubolyam, Bola Omotosho, Clemencia Solórzano, Tianna Petersen, Kranthi Vysyaraju, Stacey A Rizza, Jennifer A Whitaker, Raquel Nahra, John Baxter, Patricia Coburn, Edward M Gardner, James A Scott, Leslie Faber, Erica Pastor, Linda Makohon, Rodger A MacArthur, L Monique Hillman, Marti J Farrough, Hari M Polenakovik, Linda A Clark, Roberto J Colon, Ken M Kunisaki, Miranda DeConcini, Susan A Johnson, Cameron R Wolfe, Laura Mkumba, June Y Carbonneau, Alison Morris, Meghan E Fitzpatrick, Cathy J Kessinger, Robert A Salata, Karen A Arters, Catherine M Tasi, Ralph J Panos, Laura A Lach, Marshall J Glesby, Kirsis A Ham, Valery G Hughes, Robert T Schooley, Daniel Crouch, Leticia Muttera, Richard M Novak, Susan C Bleasdale, Ariel E Zuckerman, Weerawat Manosuthi, Supeda Thaonyen, Thaniya Chiewcharn, Gompol Suwanpimolkul, Sivaporn Gatechumpol, Sirikunya Bunpasang, Brian J Angus, Monique Anderson, Marcus Morgan, Jane Minton, Maria N Gkamaletsou, Joe Hambleton, David A Price, Martin J Llewelyn, Jonathan Sweetman, Javier Carbone, Jose R Arribas, Rocio Montejano, Jose L Lobo Beristain, Iñaki Z Martinez, Jose Barberan, Paola Hernandez, Dominic E Dwyer, Jen Kok, Alvaro Borges, Christian T Brandt, Lene S Knudsen, Nikolaos Sypsas, Costas Constantinou, Antonios Markogiannakis, Spyros Zakynthinos, Paraskevi Katsaounou, Ioannis Kalomenidis, Analia Mykietiuk, Maria F Alzogaray, Mora Obed, Laura M Macias, Juan Ebensrtejin, Patricia Burgoa, Esteban Nannini, Matias Lahitte, Santiago Perez-Patrigeon, José Arturo Martínez-Orozco, Juan Pablo Ramírez-Hinojosa

Publikováno v: The Lancet. Respiratory Medicine
INSIGHT FLU-IVIG Study Group 2019, ' Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG) : a double-blind, randomised, placebo-controlled trial ', The Lancet Respiratory Medicine, vol. 7, no. 11, pp. 951-963 . https://doi.org/10.1016/S2213-2600(19)30253-X

Summary Background Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical benefit for patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79744d1ee481665acd19b5c34f9741d
https://pubmed.ncbi.nlm.nih.gov/31582359

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Autor: Sara Mireya Chernilo Steinmann, Abel Jasovich, Ivars Krastins, Osvaldo Teglia, Viktors Lovcinovsk, Rashad Abyshev, Graciana Isabel Morera, Maria del Rosario Gonzalez Arzac, Dorota Górecka, Thomas Mueller, Janos Szegedi, Violetta Labij, Amal Kumar Bhattacharya, Diego Maurizi, Manuel Jose Barros Monge, Parthiv Mehta, Mario Andres Calvo Arellano, Zsolt Pápai-Székely, K.N. Mohar Rao, Moises Acuna Kaldman, Peter Kujath, F.J. Meyer, Mahabala Chakrapan, Alexander Gorelov, Piotr Nalepa, Valdimir Hodzhev, Gerardo Amaya Tapia, Vladislav Novozhenok, Oliver Schmalz, Lily Llorens, Norbert Vetter, Eduardo Noriega, Dimitar Popov, Vita Svarcberga, Deepak Talwar, Joachim Bargon, Dirk Thye, Ricardo Lamberghini, Valentina Ionescu, Achim Lies, Maria Antonia Mastruzzo, V O Sushko, Tom Schaberg, Jerzy Kozielski, Jorge Corral, Barbara Rogala, Pablo Antonio Gaete Gutierrez, Alla L. Esina, Wolfgang Schütte, María Eugenia Oliva, Roman S. Kozlov, Carolina Eugenia Chahin Anania, Angel Ramon Minguez, Ognian Georgiev, Konstantin Zhidkov, Josef Bolitschek, Vadim Vizir, Thorsten Bauer, Sven Glaeser, Ian A. Critchley, Oleksandr Dziublyk, Jon Lee, Analia Mykietiuk, Carlos Ramos, Georgiy V. Dzyak, Stefan Krueger, Hanna Szelerska-Twardosz, George H. Talbot, Mihai Marius Muresan, Mykhaylo Borscchivskyy, Christian G. Remolif, Oleg A. Khrustalev, Adam Antczak, Yuriy M. Mostovoy, Pabio Gustavo Scapellato, Rosen Marinov, Oleg Kraydaschenko, Tomasz Grodzicki, H. David Friedland, George D'Souza, Milkana Simeonova, Rafal Harat, Svetlana Sobchenko, Hartmut Kern, Javier Altclas, Eduardo Demetrio Matos Prado, Arturo Jauregui Cruz, Marinka Peneva, Vasily Trofimov, Sergey Yakovlev, Tomasz Kachel, Veronika B. Popova, Maria Isabel Enriqueta Campos Barker, Rolf Bergmann, Ryszarda Chazan, Carmen Georgeta Fierbinteau, Peter Hammerl, Sándor Molnár, Andrzej Szczeklik, Paul B. Eckburg, Janusz Milanowski, Karina Jahnz—Rö, Tobias Welte, Viesturs Silins, Iwona Grzelewska—Rzymowska, Josef Eckmayr, Bernard Panaszek, Irina Andreeva, Eduardo Giugno, Luminta Gabriela Ambert, Sylvia Susana Muñoz Vejar, Jacek Juszczak, Ilona Vinkler, Carlos E. Bergallo, Malgorzata Wróbel-Rajzer, Marina Balyuzek, Yuri A. Antonovsky, Dariusz Jastrzebsk, G.S. Malpani, Cristina Mihaela Tanaseanu, Hristo Metev, Andrzej Marciniak, Donald E. Low, Germán Ambasch, Thomas M. File, Iurii S. Rudyk

Publikováno v: Journal of Antimicrobial Chemotherapy. 66:iii33-iii44

Objectives Ceftaroline (active form of the prodrug ceftaroline fosamil) is a novel cephalosporin with activity against pathogens commonly associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and Gram-negative pathoge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4984415e3d63f3ff3d554a545309a453
https://doi.org/10.1093/jac/dkr097

[Clinical features and outcome of community-acquired methicillin-resistant Staphylococcus aureus pneumonia]

Autor: Mora, Obed, Carolina, García-Vidal, Pedro, Pessacq, Analia, Mykietiuk, Diego, Viasus, Laura, Cazzola, M Angeles, Domínguez, Anibal, Calmaggi, Jordi, Carratalà

Publikováno v: Enfermedades infecciosas y microbiologia clinica. 32(1)

The aim of this study is to describe the epidemiological and clinical features, treatment and prognosis of community-acquired pneumonia (CAP) caused by methicillin-resistant Staphylococcus aureus (MRSA) in two different geographic regions where commu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2ddd04da4d9c7fd2471aff8b3f5767f8
https://pubmed.ncbi.nlm.nih.gov/23473825